LIPITOR (atorvastatin calcium) by Viatris (2) is selective, competitive inhibitor of hmg-coa reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme a to mevalonate, a precursor of sterols, including cholesterol. First approved in 1996.
Drug data last refreshed Yesterday
Lipitor (atorvastatin calcium) is an oral HMG-CoA reductase inhibitor (statin) approved in 1996 for type 2 diabetes mellitus management. It works by selectively inhibiting HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol production and increasing hepatic LDL receptor expression to enhance cholesterol clearance. Lipitor is a foundational lipid-lowering therapy widely used in cardiovascular risk reduction, though it now faces substantial generic competition and is approaching loss of exclusivity.
selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme A to mevalonate, a precursor of sterols, including cholesterol. In animal models, LIPITOR lowers plasma cholesterol and lipoprotein levels by inhibiting HMG-CoA…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Bioequivalence Study Between "Dong-A Atorvastatin Tab" and "Lipitor Tab"
Actual Use Trial of Atorvastatin Calcium 10 mg
Bioavailability Study of Amlodipine Besylate/Atorvastatin Calcium Tablets 10/80 mg Under Fasting Condition
Bioavailability Study of Amlodipine Besylate/Atorvastatin Calcium Tablets 10/80 mg Under Fed Condition
Special Drug Use-Results Survey of Lipitor Tablets
Worked on LIPITOR at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moLipitor creates limited career opportunities within its brand team given the mature, generic-dominated market; remaining roles focus on managed care contracting, patient assistance programs, and specialty pharmacy partnerships rather than primary care field promotion. Relevant skills include generic pricing strategy, prior authorization optimization, and payer relationship management in a commoditized statin market. Currently, zero open positions are linked to this product, reflecting its mature commercial stage and reduced commercial infrastructure investment.